Triple-negative breast cancer (TNBC), defined by the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2), represents 12-17% of all breast cancer cases (2). Here, ERBB2 is linked to triple-negative breast carcinoma.